#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Biotinidase deficiency MELAS syndrome Philadelphia positive acute lymphocytic leukaemia Cardiac amyloidosis Kearns-Sayre syndrome Skin angiosarcoma Plasma cell myeloma recurrent Malignant central nervous system neoplasm Lymphatic malformation Microscopic polyangiitis Thermal burn Hepatic cirrhosis Follicular lymphoma stage II Waldenstrom's macroglobulinaemia refractory Sickle cell anaemia More trials…

    Learn about Rare Diseases

    Prolymphocytic leukaemia Leiomyosarcoma recurrent – Treatment Netherton’s syndrome Rhabdomyosarcoma recurrent – Basic Information Amyotrophic lateral sclerosis – Treatment Marginal zone lymphoma refractory Idiopathic inflammatory myopathy – Life with Disease Ehlers-Danlos syndrome – Diagnostics Primary hyperoxaluria – Life with Disease Haemophilia A with anti factor VIII – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tradipitant Asparaginase Vrdn-001 Camonsertib Dexmedetomidine Hydrochloride Salbutamol Sulfate Ph. Eur. MEGESTROL ACETATE Belumosudil Mesilate Bi 685509 Prax-628 Obeticholic Acid Tarlatamab Neostigmine Methylsulfate ALPROSTADIL Floxuridine Elexacaftor Ly4100511 Spartalizumab Skb264 Co-Trimoxazole More therapies…

    Learn about Your Condition

    Invasive breast carcinoma Coagulopathy Rhinitis allergic Hydrocephalus Actinic cheilitis Oedema peripheral Hodgkin's disease refractory Amyotrophic lateral sclerosis Lichen sclerosus Immune-mediated myositis Bladder cancer Eye inflammation Arginase deficiency Thrombolysis Parkinson's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Metastatic renal cell carcinoma

  • Study of Axitinib and Pembrolizumab for Patients with Advanced or Metastatic Papillary Renal Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Axitinib
    • Pembrolizumab
    France

  • Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Cabozantinib
    • Ipilimumab
    • Nivolumab
    Czechia Germany Greece Italy Poland Romania +1

  • Study of Axitinib and Immune Checkpoint Inhibitors for Patients with Untreated Advanced or Metastatic Kidney Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    • Renal cell carcinoma
    France Germany Poland Spain

  • Study of Pembrolizumab and Epacadostat vs Standard Treatment for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Pazopanib
    • Pembrolizumab
    • Sunitinib
    Spain

  • Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Pembrolizumab
    • Sunitinib
    Czechia France Germany Hungary Ireland Poland +1

  • Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma stage IV
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    • Sunitinib
    Austria Belgium Czechia Denmark Finland France +7
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!